Rheumatoid Arthritis (RA) is a chronic, progressive
and currently incurable autoimmune disease that primarily affects the
joints. It is characterized by synovial inflammation and gradual bone
erosion over many years. Disease progression results in stiffness and
pain, especially in the hands and feet, which hinders mobility. Without
treatment, the disease leads to joint destruction and disability.
The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.
Browse Detail Report With TOC @ http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022
The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-α inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-α inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-α inhibitors.
Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA. Despite the superior efficacy of recently marketed therapies over traditional DMARD therapies, there is a need to improve safety in the therapeutic landscape. Elevated rates of infection are a frequent consequence of the immunosuppression involved in treatments, but this is required to suppress the autoimmune responses responsible for the symptoms of the condition.
Request A Sample copy of This Report @ http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022/request-sample
Scope
Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017
Cardiovascular Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/cardiovascular-disorders-drug-development-pipeline-review-2017
The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market.
Browse Detail Report With TOC @ http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022
The RA therapeutic market has become very competitive due to the high number of new drug approvals. Competition is fierce, particularly among TNF-α inhibitors, which dominate the treatment market for RA patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD). Despite this, 30% of RA patients fail to attain a clinical response when treated with TNF-α inhibitors. However, other targeted programs, as well as newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF-α inhibitors.
Recently published study results of Xeljanz have shown a significant reduction in the risk of developing cardiac diseases such as heart attack and stroke in patients with RA. Despite the superior efficacy of recently marketed therapies over traditional DMARD therapies, there is a need to improve safety in the therapeutic landscape. Elevated rates of infection are a frequent consequence of the immunosuppression involved in treatments, but this is required to suppress the autoimmune responses responsible for the symptoms of the condition.
Request A Sample copy of This Report @ http://www.hexareports.com/report/rheumatoid-arthritis-therapeutics-in-south-east-asia-markets-to-2022/request-sample
Scope
- What are the competitive advantages of the existing novel drugs?
- Which classes of novel drugs are most prominent in the pipeline?
- What is the potential for pipeline products to address unmet needs in the RA market?
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
- Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/neurodegenerative-disorders-drug-development-pipeline-review-2017
Cardiovascular Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/cardiovascular-disorders-drug-development-pipeline-review-2017
No comments:
Post a Comment